Clinical Trials Browser

Phase 1 × INDUSTRY × enzalutamide × Clear all

NCT03460977 2026-06-05

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Phase 1 Recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT05997615 2026-06-04

AMX-500

Phase 1 Recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT04221542 2026-05-29

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Recruiting

Bites and Stings, Prostatic Neoplasms

NCT07570979 2026-05-28

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Phase 1 Recruiting

Prostate Adenocarcinoma

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Phase 1 Recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT07277270 2026-01-07

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Phase 1 Recruiting

Prostatic Neoplasms

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Phase 1 Completed

120 enrolled 28 charts

Prostatic Neoplasms, Castration-Resistant

NCT04094519 2024-11-20

A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT03776968 2024-10-23

A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Phase 1 Completed

Metastatic Castration Resistant Prostate Cancer

NCT06332170 2024-07-18

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

49 enrolled 33 charts

BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04033328 2023-12-15

Study of ORIC-101 in Combination With Enzalutamide

Phase 1 Terminated

Prostatic Neoplasms

NCT03569280 2023-07-18

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

Phase 1 Completed

Prostatic Neoplasms

NCT04179396 2023-06-29

RAMP

Phase 1 Completed

8 enrolled 8 charts

Metastatic Castration Resistant Prostate Cancer

NCT02740985 2023-05-26

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

Phase 1 Completed

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Colorectal Neoplasms

NCT03150056 2022-08-10

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Phase 1 Terminated

73 enrolled 34 charts

Other solid neoplasm

Solid Tumours

NCT04087174 2022-07-13

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Phase 1 Completed

Neoplasm Metastasis, Prostatic Neoplasms

NCT01362374 2022-01-12

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03774056 2020-11-03

A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Phase 1 Completed

Metastatic Castration Resistant Prostate Cancer

NCT03778047 2020-11-03

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Phase 1 Completed

Metastatic Castration Resistant Prostate Cancer

NCT02215096 2020-10-22

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Completed

37 enrolled 26 charts

Neoplasms

NCT00510718 2019-10-03

A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Phase 1 Completed

140 enrolled 30 charts

Neoplasms, Prostatic Neoplasms

NCT01597193 2019-05-08

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Phase 1 Completed

101 enrolled 33 charts

Breast Neoplasms

NCT01565928 2019-04-22

Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer

Phase 1 Completed

23 enrolled 14 charts

Prostatic Neoplasms

NCT02225093 2017-06-27

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT01911728 2017-06-26

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Phase 1 Completed

Pharmacokinetics of MDV3100

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Phase 1 Withdrawn

Neoplasms

NCT01902251 2014-09-09

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

Phase 1 Completed

Prostatic Neoplasms

NCT01911741 2013-07-30

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Phase 1 Completed

Healthy Subjects